177lu Psma I&t

Lutetium (177Lu) Zadavotide Guraxetan (177Lu PSMA I&T) is a radiopharmaceutical used in targeted therapy for prostate cancer. Administered intravenously, it delivers radiation directly to prostate-specific membrane antigen (PSMA) positive cells. This localized approach supports pain relief and disease management. Short version: Targeted radiopharmaceutical for prostate cancer treatment using PSMA targeting.

Lutetium (177Lu) Zadavotide Guraxetan is used in targeted radioligand therapy for metastatic castration-resistant prostate cancer (mCRPC) in adults. It binds to prostate-specific membrane antigen (PSMA) on cancer cells, delivering therapeutic radiation to reduce tumor burden and manage symptoms. Patients often seek this treatment when other therapies are no longer effective. It is not a first-line option but may be considered after standard treatments. what is lutetium psma i&t used for

After administration, Lutetium (177Lu) Zadavotide Guraxetan works by targeting PSMA-expressing cells, which may lead to reduced pain associated with bone metastases. Some patients report temporary fatigue or nausea following treatment. These effects are generally mild to moderate and vary by individual. Monitoring is recommended to assess response and manage any discomfort.

Lutetium (177Lu) Zadavotide Guraxetan should only be handled and administered by trained healthcare professionals in a controlled setting. Pregnant individuals and those planning pregnancy should avoid exposure due to radiation risks. Patients must follow specific hydration and urinary elimination protocols to minimize radiation exposure to others. Regular follow-up is essential to monitor treatment progress and side effects.

No specific drug-drug interactions have been established with Lutetium (177Lu) Zadavotide Guraxetan. However, caution is advised when combining with other systemic cancer therapies or medications affecting bone marrow function. Alcohol and certain supplements may influence overall treatment tolerance. Patients should disclose all medications to their healthcare provider before starting therapy.